CETUXIMAB WEEKLY (Q1W) VERSUS EVERY TWO WEEKS (Q2W) PLUS FOLFOX4 AS FIRST-LINE THERAPY IN PATIENTS (PTS) WITH KRAS WILD-TYPE (WT) METASTATIC COLORECTAL CANCER (MCRC)

被引：0

作者：

Ciuleanu, Tudor ^{[1
]}

Nikolic, Vladimir ^{[2
]}

Shacham-Shmueli, Einat ^{[3
]}

Vrbanec, Damir ^{[4
]}

Plate, Signe ^{[5
]}

Mrsic-Krmpotic, Zrinka ^{[6
]}

Kahan, Zsuzsanna ^{[7
]}

Purkalne, Gunta ^{[8
]}

Brodowicz, Thomas ^{[9
]}

Zielinski, Christoph ^{[9
]}

机构：

[1] Inst Oncol, IL-69978 Cluj Napoca, Romania

[2] Inst Oncol & Radiotherapy, Belgrade, Serbia

[3] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, Dept Oncol, Tel Aviv, Israel

[4] Univ Zagreb, Univ Hosp Zagreb Rebro, HR-10002 Zagreb, Croatia

[5] Latvian Ctr Oncol, Riga, Latvia

[6] Univ Zagreb, Univ Hosp Tumors, HR-10002 Zagreb, Croatia

[7] Semmelweis Univ, Dep Diagnost Radiol & Oncotherapy, Budapest, Hungary

[8] P Stradins Univ Hosp, Riga, Latvia

[9] Med Univ Vienna, Div Clin Oncol, Vienna, Austria

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：v22 / v22

页数：1